Anti-abortion groups furious as FDA approves generic abortion pill | US news

In a decision that left the defenders of the anti-abortion, the US Food and Drug Administration (FDA) discreetly approved a request for the manufacture of a new abortion pill earlier this week.

Thanks to approval, a company called Evita Solutions will be able to manufacture its generic version of Mifepristone, one of the two drugs generally used in most American drug abortions. A generic version of Mifepristone, which was approved for the first time as a brand medication in 2000, is already available on the market.

However, the approval was amazed and exasperated abortion enemies, who have spent the three years since the reversal in 2022 of Roe against Wade by putting pressure on the federal government to slow down access to mifepristone. Robert F Kennedy Jr, the Secretary of Health, announced last month that his department would examine the security of mifepristone.

“The FDA had promised to make a security review from top to bottom of the drug at chemical abortion, but instead, they were simply new versions in the light of green,” said Josh Hawley, a republican senator from Missouri and an opponent of fierce abortion.

Kristan Hawkins, president of the powerful students of the anti-abortion group for Life of America, described the approval of “achieving real failure”.

“This is a task on the Trump presidency,” she added in a statement.

To strengthen their attack on mifepristone, anti-abortion activists have recently seized an April article by the Center for Ethics and Public Policy, a right bank, saying that almost 11% of women experience septicemia or other serious complications within 45 days of taking mifepristone. In his letter announcing the examination of mifepristone, Kennedy cited the article in the center.

But this document was not evaluated by peers or published in a medical journal, and the experts discovered several faults there. For example, he has extra -reflective pregnancies – in which an embryo implants somewhere outside the uterine lining – as a serious complication. Miffepristone does not cause ultra-ectopic pregnancies.

Meanwhile, more than 100 studies, carried out over three decades and dozen countries, have concluded that mifepristone is a safe and effective tool for ending a pregnancy.

Supporters of abortion rights celebrated the news of the FDA approval, proclaiming a victory for sustained medicine for evidence.

“By widening generic options, the agency strengthens the impeccable security file of Mifepristone,” said Kiki Freedman, co-founder and CEO of the telemedicine supplier Hey Jane, in a statement.

“At a time when political motivation attacks threaten to undermine science and restrict care, it is essential to emphasize that science could not be clearer.”

The health service did not immediately respond to a request for comments. However, a spokesperson for the department told New York Times in a statement that “the FDA has a very limited discretion to decide whether to approve a generic medication”.

“According to the law, the Secretary of Health and Social Services must approve a request if it shows that the generic drug is identical to the brand medication,” said the spokesperson.